Tevogen Bio Holdings Inc
TVGNW0.036USD
-0.006-14.69%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Tevogen Bio Holdings Inc Company
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
Tevogen Bio Holdings Inc Info
Ticker SymbolTVGNW
Company nameTevogen Bio Holdings Inc
IPO dateNov 04, 2021
CEODr. Ryan Saadi, M.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address15 Independence Boulevard, Suite #210
CityWARREN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07059
Phone16468078832
Websitehttps://tevogen.com/
Ticker SymbolTVGNW
IPO dateNov 04, 2021
CEODr. Ryan Saadi, M.D.
Company Executives of Tevogen Bio Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director
Independent Director
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director
Independent Director
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Curtis Patton
Dr. Curtis Patton
Independent Director
Independent Director
--
--
Dr. Keow Lin (Lindee) Goh
Dr. Keow Lin (Lindee) Goh
Independent Director
Independent Director
--
--
Mr. Sadiq Khan
Mr. Sadiq Khan
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Neal Flomenberg, M.D.
Dr. Neal Flomenberg, M.D.
Chief Scientific Officer and Global R&D Lead
Chief Scientific Officer and Global R&D Lead
--
--
Mr. Jeffrey Feike
Mr. Jeffrey Feike
Independent Director
Independent Director
--
--
Ms. Susan M. Podlogar
Ms. Susan M. Podlogar
Independent Director
Independent Director
--
--
Mr. Victor Sordillo
Mr. Victor Sordillo
Independent Director
Independent Director
--
--
Mr. Kirti Desai
Mr. Kirti Desai
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ryan Saadi, M.D.
Dr. Ryan Saadi, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
63
11.62M
0.00%
-2.83M
2025Q3
65
12.26M
0.00%
-2.93M
2025Q2
63
12.49M
0.00%
-4.41M
2025Q1
66
12.49M
0.00%
-4.61M
2024Q4
69
14.15M
0.00%
-3.24M
2024Q3
73
15.05M
0.00%
-2.82M
2024Q2
74
15.32M
0.00%
-2.48M
2024Q1
73
15.60M
0.00%
-2.66M
2023Q4
71
16.67M
0.00%
-144.22K
2023Q3
71
15.71M
0.00%
-753.59K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tenor Capital Management Co., L.P.
125.00K
0%
--
--
Sep 30, 2025
Q Global Advisors, LLC
132.15K
0%
--
--
Sep 30, 2025
Highbridge Capital Management, LLC
1.15M
0%
-344.76K
-23.04%
Sep 30, 2025
Parallax Volatility Advisers, L.P.
844.57K
0%
-61.30K
-6.77%
Sep 30, 2025
Fourworld Capital Management LLC
1.45M
0%
--
--
Sep 30, 2025
Corbin Capital Partners, L.P.
1.16M
0%
--
--
Dec 31, 2024
Calamos Advisors LLC
1.00M
0%
--
--
Sep 30, 2025
Greenland Capital Management LP
703.03K
0%
--
--
Sep 30, 2025
Polar Asset Management Partners Inc.
700.00K
0%
--
--
Sep 30, 2025
MMCAP Asset Management
650.00K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Tevogen Bio Holdings Inc?
The top five shareholders of Tevogen Bio Holdings Inc are:
Tenor Capital Management Co., L.P. holds 125.00K shares, accounting for 0.00% of the total shares.
Q Global Advisors, LLC holds 132.15K shares, accounting for 0.00% of the total shares.
Highbridge Capital Management, LLC holds 1.15M shares, accounting for 0.00% of the total shares.
Parallax Volatility Advisers, L.P. holds 844.57K shares, accounting for 0.00% of the total shares.
Fourworld Capital Management LLC holds 1.45M shares, accounting for 0.00% of the total shares.
Tenor Capital Management Co., L.P. holds 125.00K shares, accounting for 0.00% of the total shares.
Q Global Advisors, LLC holds 132.15K shares, accounting for 0.00% of the total shares.
Highbridge Capital Management, LLC holds 1.15M shares, accounting for 0.00% of the total shares.
Parallax Volatility Advisers, L.P. holds 844.57K shares, accounting for 0.00% of the total shares.
Fourworld Capital Management LLC holds 1.45M shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Tevogen Bio Holdings Inc?
The top three shareholder types of Tevogen Bio Holdings Inc are:
Other
Other
How many institutions hold shares of Tevogen Bio Holdings Inc (TVGNW)?
As of 2025Q4, 63 institutions hold shares of Tevogen Bio Holdings Inc, with a combined market value of approximately 11.62M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Tevogen Bio Holdings Inc?
In --, the -- business generated the highest revenue for Tevogen Bio Holdings Inc, amounting to -- and accounting for --% of total revenue.
